Free Trial

Regency Capital Management Inc. DE Purchases 140,058 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Aura Biosciences logo with Medical background

Regency Capital Management Inc. DE lifted its stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 23.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 749,482 shares of the company's stock after purchasing an additional 140,058 shares during the quarter. Aura Biosciences accounts for 2.6% of Regency Capital Management Inc. DE's portfolio, making the stock its 14th largest position. Regency Capital Management Inc. DE owned about 1.49% of Aura Biosciences worth $4,392,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in AURA. Geode Capital Management LLC increased its holdings in Aura Biosciences by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company's stock worth $8,327,000 after buying an additional 3,972 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Aura Biosciences by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company's stock valued at $227,000 after purchasing an additional 5,930 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Aura Biosciences in the 4th quarter valued at $50,000. Bank of America Corp DE boosted its holdings in Aura Biosciences by 20.5% in the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company's stock worth $422,000 after purchasing an additional 8,709 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Aura Biosciences by 5,766.9% during the first quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock worth $57,000 after buying an additional 9,573 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Stock Performance

Shares of AURA traded up $0.06 during mid-day trading on Monday, hitting $6.77. The company's stock had a trading volume of 141,314 shares, compared to its average volume of 210,198. The stock's 50-day moving average is $6.23 and its two-hundred day moving average is $6.66. The firm has a market capitalization of $340.33 million, a PE ratio of -3.56 and a beta of 0.45. Aura Biosciences, Inc. has a one year low of $4.35 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.08). Analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Insider Activity

In other Aura Biosciences news, insider Anthony S. Gibney acquired 50,000 shares of the business's stock in a transaction on Friday, May 16th. The stock was purchased at an average price of $4.90 per share, for a total transaction of $245,000.00. Following the transaction, the insider owned 58,452 shares in the company, valued at $286,414.80. This trade represents a 591.58% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Michael Johnson purchased 20,000 shares of Aura Biosciences stock in a transaction that occurred on Friday, May 16th. The shares were bought at an average price of $4.90 per share, for a total transaction of $98,000.00. Following the transaction, the director owned 166,167 shares in the company, valued at $814,218.30. This represents a 13.68% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 5.40% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AURA shares. HC Wainwright raised Aura Biosciences to a "buy" rating and set a $22.00 price objective on the stock in a research note on Wednesday, May 28th. JMP Securities restated a "market outperform" rating and issued a $19.00 price objective on shares of Aura Biosciences in a research note on Friday, May 23rd. Finally, Citigroup reaffirmed an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Aura Biosciences has a consensus rating of "Buy" and a consensus target price of $22.00.

View Our Latest Stock Analysis on AURA

Aura Biosciences Profile

(Free Report)

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Featured Stories

Institutional Ownership by Quarter for Aura Biosciences (NASDAQ:AURA)

Should You Invest $1,000 in Aura Biosciences Right Now?

Before you consider Aura Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.

While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines